IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Jason Parnes

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 12.9

ph-index = 10

Forward Citations = 318(Granted Patents)


Company Filing History:

goldMedal18 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents

Years Active: 2006-2022

Loading Chart...
Loading Chart...
18 patents (USPTO):
1. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),
2. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),
3. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),
4. 9783505 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2017-10-10),
5. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),
6. 9556126 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2017-01-31),
7. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),
8. 9156798 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2015-10-13),
9. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),
10. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway (2013-08-13),
11. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2013-07-23),
12. 8383634 - Methods of treatment using heteroaryl compounds and compositions thereof (2013-02-26),
13. 8372976 - Methods of treatment comprising the administration of heteroaryl compounds (2013-02-12),
14. 8110578 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2012-02-07),
15. 7981893 - Heteroaryl compounds, compositions thereof, and methods of treatment therewith (2011-07-19),

Title: Discovering the Innovations of Jason Parnes in mTOR Kinase Inhibition

Introduction

Jason Parnes, an innovative inventor based in San Diego, California, has made significant contributions to the field of pharmaceutical research with a focus on mTOR kinase inhibitors. With a remarkable portfolio of 18 patents, Parnes continues to push the boundaries of biomedical science through his imaginative approach to chemical compounds.

Latest Patents

Among his recent inventions, Parnes has developed substituted pyrazino[2,3-b]pyrazines that act as mTOR kinase inhibitors. His latest patents detail heteroaryl compounds and methods for preparing these innovative chemical structures. Specifically, these patents include methods for contacting compounds of specific formulas and involve cyclization processes that further enhance the efficacy of the compounds.

Career Highlights

Jason Parnes is currently employed at Signal Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry. Throughout his career, Parnes has demonstrated an unwavering dedication to research and development, paving the way for potential therapies that could impact numerous health conditions related to mTOR pathways.

Collaborations

In his professional journey, Parnes collaborates with talented colleagues including Deborah Mortensen and John J. Sapienza. Together, they form a dynamic team that drives innovation within the fast-paced environment of pharmaceutical research.

Conclusion

In summary, Jason Parnes is a noteworthy inventor whose work on mTOR kinase inhibitors exemplifies the spirit of innovation in the pharmaceutical sector. His extensive patent portfolio and collaborative efforts reinforce the importance of research in developing advanced therapeutic solutions. As he continues to explore new frontiers, the impact of his inventions is sure to be felt across the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…